You won't find them on financial statements, and they're not easily traded. But invisible assets can hold significant value, ...

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly ...

Over the past six months, Synchrony Financial’s stock price fell to $66.59. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 4.8%. This ...

Fourth quarter results reflect revenue growth, margin expansion and order momentum. Revenue increased 17% to $143.4 million, ...

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBI ...

Good day, and welcome to the B&G Foods Fourth Quarter and Fiscal 2025 Earnings Call. Today's call, which is being recorded, is scheduled to last about 1 hour, including remarks by B&G Foods management ...

Due to the impact of portfolio rationalization, and considering the challenging business environment, the company expects a ...

Welcome to our conference call to review Q4 and full year 2025 and to look into 2026. To begin, Bill will share his perspective on our business development, the progress we've made in our ...

As Washington state lawmakers consider an income tax on earnings over $1 million, a 1933 state Supreme Court decision still reverberates.

("ESS," "ESS, Inc." or the "Company") (NYSE:GWH), a leading manufacturer of iron flow long-duration energy storage ("LDES") systems for commercial and utility-scale applications, today announced ...

The INDEXO financial services group concluded 2025 as a year of strong growth across all key areas of operation. IPAS INDEXO, the parent company of the INDEXO financial services group, generated a pro ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...